Treatment of dyslipidemia in pre- and postmenopausal women with and without known atherosclerotic cardiovascular disease
Division of Cardiovascular Disease, University of Alabama at Birmingham, UAB Station - LHR 310, Birmingham, AL 35294, USA.Current Cardiology Reports (Impact Factor: 1.93). 10/2001; 3(5):401-7. DOI: 10.1007/s11886-001-0057-2
Cardiovascular disease is the primary cause of death among women in the United States, in part due to a very high prevalence of dyslipidemia. Clinical trials have shown that low-density lipoprotein cholesterol-lowering therapy can decrease angiographic progression of coronary disease and decrease clinical events among women and men. Although hormone replacement therapy has beneficial effects on the lipoprotein profile, its role in cardiovascular disease prevention remains unclear. The recently released Third Report of the National Cholesterol Education Program Expert Panel provides detailed guidelines for the management of dyslipidemia in women, with a focus on low-density lipoprotein cholesterol and intensity guided by risk of cardiovascular events.
- [Show abstract] [Hide abstract]
ABSTRACT: Cardiovascular disease (CVD) and diabetes are chronic diseases distributed worldwide. Both of them share of some common risk factors and have some common pathophysiological changes. CVD and diabetes are a huge burden on the health care system of every government and its population. Therefore, the early prevention and treatment of diabetes, insulin resistance and CVD has a significant role for public health and the health care system. Dietary fiber has received recognition for reducing the risk of developing both CVD and diabetes. The implication is that dietary fiber may have therapeutic benefits in predia-betic metabolic conditions and in preventing the cardiovascular complications. The effect of dietary fiber on the common risk factors and possibly relative gene expression may reduce the morbidity of these diseases. However, the amount of total dietary fiber consumed and the chemical and physiological properties of different fiber sources will determine the effectiveness in prevention or treatment of CVD, insulin resistance or type 2 diabetes.Frontiers in Cardiovascular Health, 01/2003: pages 227-241;
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.